{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:52:41Z","timestamp":1794185561228,"version":"4.8.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec id=\"ab-eoi250053-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Intravitreal complement inhibitors injections (IVCIs) slowed progression of geographic atrophy (GA) lesions in several registration phase 3 trials although without benefit for prespecified secondary functional vision outcomes. Patient acceptability of these therapies needs further exploration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify the acceptability of IVCI therapy to United Kingdom patients with GA, assuming vision outcome benefits are expected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cross-sectional study took place at 9 geographically dispersed UK National Health Service centers from April 2023 to April 2024 among 153 participants with treatment-naive GA in at least 1 eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>GA in at least 1 eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      Main outcomes were (1) acceptability of IVCI therapy based on completion of validated acceptability questionnaire. Participants were provided with a treatment information leaflet coproduced by a patients with lived experience of GA to inform them about the risks and benefits of IVCI for GA, assuming there were vision outcome benefits to this treatment and (2) response to the EuroQol 5-dimension with a vision bolt-on questionnaire to assess general health and vision-related quality of life. Spearman rank correlations and \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      tests were used to explore associations between acceptability levels and specific ocular and sociodemographic characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 153 participants were recruited (93 [60%] women; mean [SD] age, 82 [7]), 57 (38%) of whom had bilateral foveal involvement. Median (IQR) visual acuity with habitual correction in the better-seeing eye and in eyes where neither eye was better or worse was logMAR, 0.30 (0.14-0.54; approximate Snellen equivalent, 20\/40) and 0.47 (0.14-0.84; approximate Snellen equivalent, 20\/63), respectively. Among the 153 participants, 81 (53%; 95% CI, 45-61) reported IVCIs were very much or extremely acceptable under the theoretical scenarios provided. The proportion finding IVCIs acceptable rose to 82% (95% CI, 76-88) when including those who rated prospective treatment as moderately acceptable. Belief in the perceived effectiveness of the treatment (\u03c1, 0.52; 95% CI, 0.40-0.63;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and confidence in their ability to attend the eye clinic regularly (\u03c1, 0.51; 95% CI, 0.38-0.62;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) correlated with overall acceptability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250053-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>IVCI therapy for GA may be acceptable to most UK patients with GA under the assumption that there are vision outcome benefits to this treatment. While current treatments do not result in vision outcome benefits, perceived effectiveness by patients was associated with acceptability, emphasizing the desire to quantify vision functional benefit concomitant with anatomical slowing of progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.3264","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:31:10Z","timestamp":1758814270000},"page":"916","source":"Crossref","is-referenced-by-count":2,"title":["Patient-Reported Importance of Functional Benefit in Geographic Atrophy"],"prefix":"10.1001","volume":"143","author":[{"given":"Christiana","family":"Dinah","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Central Middlesex Hospital, London North West University Healthcare National Health Service Trust, London, United Kingdom"},{"name":"Department of Brain Sciences, Imperial College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Enoch","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, School of Health and Psychological Sciences, City St George\u2019s, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arevik","family":"Ghulakhszian","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Central Middlesex Hospital, London North West University Healthcare National Health Service Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Sekhon","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, City St George\u2019s, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"DeSalvo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, University Hospital Southampton National Health Service Trust, Southampton, United Kingdom"},{"name":"Ophthalmology Department, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[{"name":"Royal Berkshire Hospital National Health Service Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Banerjee","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devaki","family":"Nayak","sequence":"additional","affiliation":[{"name":"Shrewsbury and Telford National Health Service Trust, Shrewsbury, United Kingdom"},{"name":"Research and Development, Keele University, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Amoaku","sequence":"additional","affiliation":[{"name":"University of Nottingham, Queens Medical Centre, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Shiew","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka","family":"Osoba","sequence":"additional","affiliation":[{"name":"University Hospitals of Bristol & Weston, National Health Service Foundation Trust, Bristol, United Kingdom"},{"name":"Torbay Hospital, South Devon National Health Service Foundation, Torquay, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, School of Health and Psychological Sciences, City St George\u2019s, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna J.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, School of Health and Psychological Sciences, City St George\u2019s, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi250053r1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration.","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi250053r2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target.","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"issue":"2","key":"eoi250053r3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review.","volume":"36","author":"Desai","year":"2022","journal-title":"Eye (Lond)"},{"issue":"10411","key":"eoi250053r4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"issue":"10411","key":"eoi250053r5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"eoi250053r6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009300.pub3","article-title":"Complement inhibitors for age-related macular degeneration.","volume":"6","author":"Tzoumas","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"eoi250053r9","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41433-023-02571-3","article-title":"Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: a mixed-methods study.","volume":"37","author":"Enoch","year":"2023","journal-title":"Eye (Lond)"},{"issue":"1","key":"eoi250053r10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework.","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"eoi250053r11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12913-022-07577-3","article-title":"Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions.","volume":"22","author":"Sekhon","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"eoi250053r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075713","article-title":"Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.","volume":"14","author":"Dinah","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"eoi250053r13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2014.09.004","article-title":"An exploratory study to test the impact on three \u201cbolt-on\u201d items to the EQ-5D.","volume":"18","author":"Yang","year":"2015","journal-title":"Value Health"},{"issue":"4","key":"eoi250053r14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10198-019-01156-w","article-title":"A vision \u2018bolt-on\u2019 increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.","volume":"21","author":"Gandhi","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"12","key":"eoi250053r15","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1038\/s41433-021-01414-3","article-title":"Predicting quality of life in AMD patients-insights on the new NICE classification and on a bolt-on vision dimension for the EQ-5D.","volume":"35","author":"De Sousa Peixoto","year":"2021","journal-title":"Eye (Lond)"},{"issue":"14","key":"eoi250053r16","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1167\/iovs.16-20361","article-title":"Functional Reading Independence (FRI) Index: a new patient-reported outcome measure for patients with geographic atrophy.","volume":"57","author":"Kimel","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi250053r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6490","article-title":"Slowing Geographic Atrophy-Hopeful Progress or Uncertain Benefit.","author":"Jia","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi250053r18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR.","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi250053r19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jamaophthalmol.2024.1269","article-title":"Pegcetacoplan treatment and consensus features of geographic atrophy over 24 months.","volume":"142","author":"Fu","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"eoi250053r20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ajo.2025.04.016","article-title":"Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE.","volume":"276","author":"Wykoff","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi250053r21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/IAE.0000000000003796","article-title":"Complement inhibition for geographic atrophy: review of salient functional outcomes and perspective.","volume":"43","author":"Spaide","year":"2023","journal-title":"Retina"},{"key":"eoi250053r22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2025.02.012","article-title":"Visual function benefit after treatment with pegcetacoplan: microperimetry analysis from the phase 3 Oaks trial.","volume":"273","author":"Chakravarthy","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi250053r23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1167\/iovs.61.5.63","article-title":"Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration.","volume":"61","author":"K\u00fcnzel","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"eoi250053r24","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(97)30079-7","article-title":"Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity.","volume":"104","author":"Sunness","year":"1997","journal-title":"Ophthalmology"},{"issue":"5-a Suppl","key":"eoi250053r25","first-page":"S2","article-title":"Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"eoi250053r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010685","article-title":"Effectiveness of community versus hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHOES): a virtual non-inferiority trial.","volume":"6","author":"Reeves","year":"2016","journal-title":"BMJ Open"},{"key":"eoi250053r27","doi-asserted-by":"publisher","DOI":"10.1080\/17538068.2017.1340541","article-title":"Patient engagement: Qualitative narratives illustrate patient engagement behaviors.","author":"Sloan","year":"2023","journal-title":"J Patient Exp"},{"issue":"8","key":"eoi250053r28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41433-019-0393-3","article-title":"Socio-economic status and outcomes for patients with age-related macular degeneration.","volume":"33","author":"More","year":"2019","journal-title":"Eye (Lond)"},{"issue":"5","key":"eoi250053r29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","article-title":"The estimated prevalence and incidence of late stage age related macular degeneration in the UK.","volume":"96","author":"Owen","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi250053r30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10461-022-03796-1","article-title":"Acceptability assessment in HIV prevention and treatment intervention and service delivery research: a systematic review and qualitative analysis.","volume":"27","author":"Ortblad","year":"2023","journal-title":"AIDS Behav"},{"issue":"10","key":"eoi250053r31","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26177","article-title":"Measuring the performance of HIV self-testing at private pharmacies in Kenya: a cross-sectional study.","volume":"26","author":"Ortblad","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"eoi250053r32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40814-024-01590-5","article-title":"Telehealth group intervention for adolescents and young adults with cancer: a feasibility pilot study protocol.","volume":"11","author":"Chan","year":"2025","journal-title":"Pilot Feasibility Stud"},{"issue":"2","key":"eoi250053r33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10826-025-03007-0","article-title":"Universal Mental Health Screening in Schools: How Acceptable is this to Key Stakeholders? A Systematic Review.","volume":"34","author":"Palmer","year":"2025","journal-title":"J Child Fam Stud"},{"issue":"2","key":"eoi250053r34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/09593985.2024.2329960","article-title":"Personalizing rehabilitation for individuals with musculoskeletal impairments: feasibility of implementation of the Measures Associated to Prognostic (MAPS) tool.","volume":"41","author":"Desmarais","year":"2025","journal-title":"Physiother Theory Pract"},{"key":"eoi250053r35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2288-11-112","article-title":"Pre-validation methods for developing a patient reported outcome instrument.","volume":"11","author":"Prior","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"eoi250053r36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (REST) Committee.","volume":"8","author":"Witkin","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"eoi250053r7","unstructured":"European Medicines Agency (EMA). Syfovre (pegcetacoplan). Published September 19, 2024. Accessed February 11, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/syfovre"},{"key":"eoi250053r8","unstructured":"Evans? A. The syfovre situation. the ophthalmologist. Published February 10, 2025. Accessed February 11, 2025.https:\/\/theophthalmologist.com\/business-profession\/the-syfovre-situation"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2839343\/jamaophthalmology_dinah_2025_oi_250053_1762977498.38125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:03:20Z","timestamp":1763654600000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2839343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3264","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}